#Medsky🧪 #IDSky #mmunosky #pharmasky #publichealth Recaps the study suggests that #fostamatinib, a treatment for the blood disorder chronic immune thrombocytopenia, did not significantly decrease oxygen-free days or improve outcomes for hospitalized patients with #COVID19. @vumc-insights.bsky.social

Rigel's Fostamatinib Undergoing Phase 1 Trials for Sickle Cell Disease Treatment Rigel Pharmaceuticals has commenced a Phase 1 study evaluating the effects of Fostamatinib in sickle cell disease patients, seeking new treatment avenues.

Rigel's Fostamatinib Undergoing Phase 1 Trials for Sickle Cell Disease Treatment #None #Bethesda #Rigel_Pharmaceuticals #sickle_cell_disease #Fostamatinib

Immune-suppressing drug does not improve COVID-19 recovery: study Research shows a treatment for the chronic immune thrombocytopenia did not improve outcomes for hospitalized patients with COVID-19.

Immune-suppressing drug does not improve COVID-19 recovery news.vumc.org/2024/12/17/i... #VUMCbiostat associate prof Matt Shotwell is a lead author. Co-authors include principal biostatistician Josh DeClercq (VU MS 2018), prof Jonathan Schildcrout & lead biostatistician Li Wang. #fostamatinib

Fostamatinib for Hospitalized Adults With COVID-19 and Hypoxemia This randomized clinical trial investigates whether fostamatinib increases oxygen-free days among adults hospitalized with COVID-19 and hypoxemia.

#Fostamatinib for Hospitalized Adults With #COVID19 and #Hypoxemia: A Randomized Clinical Trial jamanetwork.com/journals/jam... #hvhebron #malinf [Text complet] @jama.com